Spots Global Cancer Trial Database for Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
Official Title: A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden
Study ID: NCT00960557
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
OXiGENE Investigational Site, Westmead, New South Wales, Australia
OXiGENE Investigational Site, South Brisbane, Queensland, Australia
OXiGENE Investigational Site, Adelaide, South Australia, Australia
OXiGENE Investigational Site, Bentleigh, Victoria, Australia
Contact Details
Name: Michael Brown, MD
Affiliation: Royal Adelaide Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jason Lickliter, MD
Affiliation: Monash Medical Centre
Role: PRINCIPAL_INVESTIGATOR
Name: Paul Mainwaring, MD
Affiliation: Mater Adult Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Michael Millward, MD
Affiliation: Sir Charles Gairdner Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
